Format

Send to

Choose Destination
See comment in PubMed Commons below
Prostate Cancer Prostatic Dis. 2009;12(4):355-60. doi: 10.1038/pcan.2009.21. Epub 2009 May 26.

First-year costs of treating prostate cancer: estimates from SEER-Medicare data.

Author information

  • 1Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA.

Abstract

Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact will also be important. The purpose of this study was to estimate mean per patient PCa-related costs during the first year following diagnosis and to examine the extent to which initial therapies are used, by initial cancer stage. Our data show that health-care costs were significant and varied by stage. With average first-year PCa-related costs of US$13,091, prevention strategies have the potential to reduce health-care costs.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk